Name: 글로벌 시장 동향
SKU: PH7211
Availability: InStock

보고서 요약(국문)

개요
전 세계 시신경염 치료 시장은 2022년 XX백만 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) XX%로 성장하여 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
시신경염(ON)은 눈에 혈액을 공급하는 시신경이 붓거나 자극을 받는 질환입니다. 시신경염은 일반적으로 자연적으로 호전됩니다. 스테로이드제는 시신경의 불편함을 완화하기 위해 때때로 사용될 수 있습니다. 스테로이드 요법의 잠재적인 부작용으로는 체중 증가, 기분 변화, 안면 홍조, 위장 장애, 불면증 등이 있습니다.
스테로이드는 정맥 주사로 가장 일반적으로 투여됩니다. 정맥 스테로이드 요법은 일반적인 시신경염 환자의 시력 회복에 큰 영향을 미치지는 않지만, 회복 속도를 높이는 데는 도움이 됩니다. 혈장 교환 요법은 스테로이드 요법이 효과가 없고 심각한 시력 손실이 지속되는 일부 환자의 시력 회복에 도움이 될 수 있는 치료법입니다. 혈장 교환 요법이 시신경염 치료에 유용하다는 연구 결과는 아직 없습니다.
시장 동향: 성장 동인 및 제약 요인
자가면역 질환의 증가
척수와 시신경을 포함하는 중추신경계는 다발성 경화증(MS)이라는 자가면역 질환의 영향을 받습니다. MS의 초기 증상으로 흔히 여겨지는 시신경염은 MS 환자의 약 50%에서 발생하는 것으로 보고되었습니다. 향후 다발성 경화증 환자 수 증가로 인해 시신경염 치료 시장이 성장할 것으로 예상됩니다. 예를 들어, 미국 다발성 경화증 협회에 따르면 미국에서 약 100만 명이 MS를 앓고 있으며, 전 세계적으로는 280만 명 이상이 MS를 앓고 있는 것으로 추산됩니다. MS 환자의 대부분은 20세에서 50세 사이에 진단받습니다.
또한, 시신경염의 유병률 증가는 예측 기간 동안 시장 성장을 견인하는 주요 요인 중 하나입니다. 또한, 2021년 시신경염 재단(The Optic Neuritis Foundation Inc.) 보고서에 따르면, 시신경염을 앓고 있는 사람은 전체 인구의 15~20%에 달하는 것으로 추정됩니다. 이처럼 질병의 유병률이 높을수록 시장 성장이 가속화됩니다.
시신경염과 다발성 경화증은 밀접한 관련이 있습니다. 이러한 강력한 연관성으로 인해 다발성 경화증 환자의 수가 증가하고 있으며, 이는 시신경염 치료에 대한 수요 증가로 이어지고 있습니다. 향상된 영상 진단 기술 및 진단 장비와 같은 의료 기술 발전은 특정 치료와 정확한 진단을 지원하여 시장 확장의 기회를 제공합니다.
시장 동향: 제약 요인
시신경염 치료 시장의 성장은 여러 요인에 의해 저해될 수 있습니다. 시신경염은 다발성 경화증과 같은 더 심각한 질환의 징후인 경우가 많다는 점을 고려해야 합니다. 시신경염 자체에 대한 전문적인 표적 치료법이 많지 않아 시장 확장을 저해할 수 있습니다. 시신경염은 종종 고용량의 코르티코스테로이드로 치료되지만, 이러한 약물은 심각한 부작용을 일으킬 수 있습니다.

환자와 의료 전문가는 이러한 부작용에 대한 불안감 때문에 특정 치료법을 선택하는 데 주저할 수 있습니다. 일부 치료법, 특히 최근에 개발되었거나 실험적인 치료법은 비용이 많이 들 수 있습니다. 낮은 보험 적용률과 높은 본인 부담금은 환자들이 이러한 치료를 받는 것을 더욱 어렵게 만들 수 있습니다.
보고서에 대한 자세한 내용은 샘플을 요청하십시오.
세그먼트 분석
전 세계 시신경염 치료 시장은 유형, 치료법, 최종 사용자 및 지역별로 세분화됩니다.
유형 세그먼트 중 스테로이드 요법 세그먼트는 시신경염 치료 시장 점유율의 약 39.7%를 차지했습니다.
스테로이드 요법, 특히 코르티코스테로이드는 항염증 효과 때문에 시신경염 치료에 자주 사용됩니다. 시신경염은 신체의 면역 체계가 시신경 섬유를 보호하는 미엘린 수초를 공격하는 염증 반응으로, 시신경의 염증을 유발합니다. 이 염증으로 인해 통증, 시력 손실 및 기타 시각 이상이 발생할 수 있습니다.

또한, 시신경염 치료에 스테로이드 요법 사용이 증가함에 따라 해당 부문의 성장이 촉진될 것으로 예상됩니다. 예를 들어, 미국 국립 의학 도서관(NLM)의 자료에 따르면 급성 시신경염 치료의 표준 치료법은 정맥 주사(IV) 코르티코스테로이드 투여입니다. 급성 시신경염 치료에서 정맥 주사보다 환자에게 더 편리하고 비용 효율적인 경구 투여 방식의 생체 동등 용량 코르티코스테로이드의 효과가 주목받고 있습니다. 이러한 요인들이 해당 부문의 성장을 견인하고 있습니다.
지역 분석
북미는 2022년 시장 점유율의 약 38.4%를 차지했습니다.
인구의 생활 방식 변화 가속화, 스트레스 증가, 비만 및 당뇨병 증가, 그리고 세균 감염 발생률 증가는 모두 북미 시장 확장에 기여하는 요인입니다. 또한, 주요 제품 출시, 제조업체 또는 시장 참여자의 집중, 주요 기업 간의 인수합병, 그리고 미국에서의 제품 승인 또한 시신경염 시장 성장에 기여하는 요인입니다. 예를 들어, 2022년 10월 미국 국립보건원(NIH) 산하 국립안연구소(NEI)는 트레테라 코퍼레이션(Trethera Corporation)에 시신경염(ON) 치료제 TRE-515 개발을 촉진하기 위해 160만 달러 규모의 신속 트랙 STTR 상용화 보조금을 지원했습니다. 트레테라 코퍼레이션은 암 및 자가면역 질환 치료를 위해 뉴클레오티드 대사를 표적으로 하는 신약 개발에 주력하고 있습니다. 따라서 이러한 요인들이 지역 성장을 촉진하고 있습니다. 아시아 태평양 지역에서 자가면역 질환 발병률이 증가함에 따라 시신경염 치료 시장을 주도할 것으로 예상됩니다. 주요 기업들이 신기술에 더욱 집중함에 따라 이 지역 시장 성장률은 더욱 높아질 것입니다.

코로나19 영향 분석
시신경염 치료 시장뿐만 아니라 더 넓은 의료 환경은 코로나19 팬데믹으로 인해 상당한 영향을 받았습니다. 팬데믹은 전 세계 공급망을 변화시켜 의약품 및 의료용품의 제조와 공급에 차질을 빚었습니다. 이로 인해 시신경염 치료제 부족 현상이 발생했을 수 있습니다.

코로나19 노출 가능성 때문에 기존 시신경염 환자, 특히 면역 체계가 약화된 환자는 표준 치료나 요법을 받는 데 어려움을 겪었을 수 있습니다. 팬데믹으로 인해 원격 의료의 도입이 가속화되었습니다. 이는 의료 서비스의 연속성을 어느 정도 제공했지만, 완전한 안과 검사와 같은 시신경염 진단 절차는 원격으로 수행하기 어려울 수 있습니다.
시장 세분화
유형별
• 특발성 시신경염
• 다발성 경화증 관련 시신경염
• 시신경척수염(NMO)
• 독성 시신경병증
• 기타
치료법별
• 스테로이드 요법
• 면역조절제 요법
• 기타 치료법
최종 사용자별
• 병원
• 클리닉
• 외래 수술 센터
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
주요 글로벌 시장 참여 기업으로는 Mallinckrodt Pharmaceuticals, Teijin Pharmaceutical Limited, AbbVie (Allergan PLC), AdvaCare 등이 있습니다. 주요 제약 회사로는 Novartis AG, Trethera Corporation, Santen Pharmaceuticals Corp, Teva Pharmaceutical Industries Ltd, Genentech, Inc, Alexion Pharmaceuticals, Inc 등이 있습니다.

보고서 구매 이유:

• 유형, 치료법, 최종 사용자 및 지역별 글로벌 시신경염 치료 시장 세분화를 시각화하고 주요 상업 자산 및 플레이어를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 시신경염 치료 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석을 담은 PDF 보고서를 제공합니다.

• 주요 플레이어의 핵심 제품을 모두 포함하는 제품 맵핑 Excel 파일을 제공합니다.

글로벌 시신경염 치료 시장 보고서는 약 69개의 표, 71개의 그림, 189페이지로 구성됩니다.
주요 고객 (2023년 기준):
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Optic Neuritis Treatment Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.
Optic neuritis (ON) is a condition in which the optic nerve, the nerve that supplies the eye, swells up or becomes irritated. Optic neuritis typically gets better by itself. Steroid medicines may occasionally be used to lessen optic nerve discomfort. Weight gain, mood swings, facial flushing, stomach discomfort, and insomnia are all potential side effects of steroid therapy.
Intravenously is the most common way to administer steroids. Although intravenous steroid therapy appears to have little effect on how much vision needs to recover in cases of typical optic neuritis, it does speed up the process. Plasma exchange therapy is a treatment that may help some patients regain their vision when steroid therapy fails and significant vision loss persists. Plasma exchange therapy has not yet been proven to be useful for treating optic neuritis in investigations.
Market Dynamics: Drivers and Restraints
The rising prevalence of autoimmune diseases
The central nervous system, which includes the spinal cord and optic nerves, is affected by the autoimmune disease known as multiple sclerosis (MS). Optic neuritis, frequently regarded as the earliest indication of MS, has been reported to occur in about 50% of MS patients. Over the projected period, the optic neuritis treatment market is anticipated to be driven by the rising number of multiple sclerosis cases. For instance, according National Multiple Sclerosis Society, nearly 1 million people in the United States are affected by MS. It’s estimated that more than 2.8 million people are living with MS worldwide. The majority of people with MS are diagnosed between the ages of 20 and 50 years.
Additionally, the increasing prevalence of optic neuritis is one of the major factors propelling market growth over the forecast period. In addition, according to The Optic Neuritis Foundation Inc. report published in 2021, an estimated 15% -20% of the people suffering from optic neuritis. Thus prevalence of the diseases accelerates the market growth.
Optic neuritis and multiple sclerosis are frequently linked. Given their secure link, the prevalence of multiple sclerosis patients is increasing, which increases the demand for treatments for optical neuritis. Medical technology developments, such as enhanced imaging methods and diagnostic equipment, support specific treatment and accurate diagnosis, which provides opportunities for market expansion.
Market Dynamics: Restraint
The optic neuritis treatment market's expansion may be hindered by a number of factors. Consider that optic neuritis is frequently a sign of deeper disorders like multiple sclerosis. Optic neuritis itself does not have many specialised, targeted treatments, which can impede market expansion. Optic neuritis is frequently treated with high dosages of corticosteroids, although these medications can have serious side effects.
Patients and healthcare professionals may be discouraged from choosing specific treatments due to anxiety about these side effects. Some treatments can be expensive, particularly those that are more recent or experimental. Low insurance coverage and high out-of-pocket costs may make it more difficult for patients to get these treatments.
For more details of the report, Request for sample
Segment Analysis
The global optic neuritis treatment marketis segmented based on type, treatment, end user and region.
The steroidal therapy segment from the type segment accounted for approximately 39.7% of optic neuritis treatment share
Due to its anti-inflammatory effects, steroidal therapy, particularly corticosteroids, is frequently used to treat optic neuritis. An inflammatory reaction, in which the body's immune system attacks the myelin sheath protecting the optic nerve fibres, frequently results in optic neuritis, an inflammation of the optic nerve. Pain, vision loss, and other visual abnormalities may result from this inflammation.
Additionally, it is anticipated that the growing usage of steroidal therapy for the treatment of optical neuritis will support segment growth. The standard of care for the treatment of acute optic neuritis, for instance, according to an NLM article, stated that the intravenous (IV) administration of corticosteroids. The effectiveness of oral delivery of a bioequivalent dose of corticosteroid, which may be more convenient for patients and cost-effective than IV administration, in the treatment of acute optic neuritis. Thus above factors boost the segment growth.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
The overall population's accelerating change in lifestyle, the rise in stress, obesity, and diabetes, as well as the rising incidence of bacterial infections, are all factors contributing to the market's expansion in North America. Additionally, important launches of products, a high concentration of manufacturers or market players, mergers and acquisitions between significant companies, and product approvals in United States are all contributing factors to the growth of the optic neuritis market.
For instance, in October 2022, the National Eye Institute (NEI), a part of the National Institutes of Health (NIH), provided Trethera Corporation a $1.6 million Fast-Track STTR commercialization grant to advance the development of TRE-515 as a treatment for optic neuritis (ON). Trethera Corporation is dedicated to developing novel drugs that target nucleotide metabolism for the treatment of cancer and autoimmune diseases. Therefore, those factors fuel regional growth. Due to the rising incidence of autoimmune diseases in this region, Asia Pacific will be expected to control the market for treating optic neuritis. The market's growth rate in this region will also be boosted by the increased focus of the major players on novel technology.
COVID-19 Impact Analysis
The optic neuritis treatment market, as well as the wider healthcare environment, has been significantly impacted by the COVID-19 pandemic. The pandemic affected the manufacturing and delivery of medicines and medical supplies by altering global supply systems. Drug shortages for treating optic neuritis may have resulted from this.
Due to the potential of COVID-19 exposure, existing optic neuritis patients, particularly those with weakened immune systems, may have had difficulties accessing standard treatments or therapies. Telemedicine's uptake was sped up by the pandemic. While this provided some continuity in healthcare services, other diagnostic procedures for optic neuritis, such as complete eye exams, may be difficult to perform remotely.
Market Segmentation
By Type
• Idiopathic Optic Neuritis
• Multiple Sclerosis-Related Optic Neuritis
• Neuromyelitis Optica (NMO)
• Toxic Optic Neuropathy
• Others
By Treatment
• Steroidal Therapy
• Immunomodulators Therapy
• Other Treatments
By End User
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Mallinckrodt Pharmaceuticals, Teijin Pharmaceutical Limited, AbbVie (Allergan PLC), AdvaCare Pharma, Novartis AG, Trethera Corporation, Santen Pharmaceuticals Corp, Teva Pharmaceutical Industries Ltd, Genentech, Inc, Alexion Pharmaceuticals, Inc and among others.
Why Purchase the Report?
• To visualize the global optic neuritis treatment market segmentation based on type, treatment, end user and region as well as understandkey commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of optic neuritis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global optic neuritis treatment market report would provide approximately 69tables, 71figures and 189 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by End User
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The rising prevalence of autoimmune diseases
4.1.1.2. The strategies adopted by the companies
4.2. Restraints
4.2.1.1. Expensive cost associated with the research and development
4.2.2. Opportunity
4.2.3. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Idiopathic Optic Neuritis*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Multiple Sclerosis-Related Optic Neuritis
7.4. Neuromyelitis Optica (NMO)
7.5. Toxic Optic Neuropathy
7.6. Others
8. By Treatment
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Steroidal Therapy *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Immunomodulators Therapy
8.4. Other Treatments
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Clinics
9.4. Ambulatory Surgical Centers
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Mallinckrodt Pharmaceuticals*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Teijin Pharmaceutical Limited
12.3. AbbVie (Allergan PLC)
12.4. AdvaCare Pharma
12.5. Novartis AG
12.6. Trethera Corporation
12.7. Santen Pharmaceuticals Corp
12.8. Teva Pharmaceutical Industries Ltd
12.9. Genentech, Inc
12.10. Alexion Pharmaceuticals, Inc
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Mallinckrodt Pharmaceuticals, 4.	Key Developments, Teijin Pharmaceutical Limited, AbbVie (Allergan PLC), AdvaCare Pharma, Novartis AG, Trethera Corporation, Santen Pharmaceuticals Corp, Teva Pharmaceutical Industries Ltd, Genentech, Inc, Alexion Pharmaceuticals, Inc

표 목록 (Tables)

List of Tables

Table 1 Global Optic Neuritis Treatment Market Value, By Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Optic Neuritis Treatment Market Value, By Treatment, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Optic Neuritis Treatment Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Optic Neuritis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Optic Neuritis Treatment Market Value, By Type, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Optic Neuritis Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 7 Global Optic Neuritis Treatment Market Value, By Treatment, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Optic Neuritis Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 9 Global Optic Neuritis Treatment Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Optic Neuritis Treatment Market Value, By End User, 2021-2030 (US$ Million)

Table 11 Global Optic Neuritis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Optic Neuritis Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Optic Neuritis Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 14 North America Optic Neuritis Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 15 North America Optic Neuritis Treatment Market Value, By End User, 2021-2030 (US$ Million)

Table 16 North America Optic Neuritis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Optic Neuritis Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 18 South America Optic Neuritis Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 19 South America Optic Neuritis Treatment Market Value, By End User, 2021-2030 (US$ Million)

Table 20 South America Optic Neuritis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Optic Neuritis Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 22 Europe Optic Neuritis Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 23 Europe Optic Neuritis Treatment Market Value, By End User, 2021-2030 (US$ Million)

Table 24 Europe Optic Neuritis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Optic Neuritis Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Optic Neuritis Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Optic Neuritis Treatment Market Value, By End User, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Optic Neuritis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Optic Neuritis Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Optic Neuritis Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Optic Neuritis Treatment Market Value, By End User, 2021-2030 (US$ Million)

Table 32 Mallinckrodt Pharmaceuticals: Overview

Table 33 Mallinckrodt Pharmaceuticals: Product Portfolio

Table 34 Mallinckrodt Pharmaceuticals: Key Developments

Table 35 Teijin Pharmaceutical Limited: Overview

Table 36 Teijin Pharmaceutical Limited: Product Portfolio

Table 37 Teijin Pharmaceutical Limited: Key Developments

Table 38 AbbVie (Allergan PLC): Overview

Table 39 AbbVie (Allergan PLC): Product Portfolio

Table 40 AbbVie (Allergan PLC): Key Developments

Table 41 AdvaCare Pharma: Overview

Table 42 AdvaCare Pharma: Product Portfolio

Table 43 AdvaCare Pharma: Key Developments

Table 44 Novartis AG: Overview

Table 45 Novartis AG: Product Portfolio

Table 46 Novartis AG: Key Developments

Table 47 Trethera Corporation: Overview

Table 48 Trethera Corporation: Product Portfolio

Table 49 Trethera Corporation: Key Developments

Table 50 Santen Pharmaceuticals Corp: Overview

Table 51 Santen Pharmaceuticals Corp: Product Portfolio

Table 52 Santen Pharmaceuticals Corp: Key Developments

Table 53 Teva Pharmaceutical Industries Ltd: Overview

Table 54 Teva Pharmaceutical Industries Ltd: Product Portfolio

Table 55 Teva Pharmaceutical Industries Ltd: Key Developments

Table 56 Genentech, Inc: Overview

Table 57 Genentech, Inc: Product Portfolio

Table 58 Genentech, Inc: Key Developments

Table 59 Alexion Pharmaceuticals, Inc: Overview

Table 60 Alexion Pharmaceuticals, Inc: Product Portfolio

Table 61 Alexion Pharmaceuticals, Inc: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Optic Neuritis Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Optic Neuritis Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 4 Global Optic Neuritis Treatment Market Share, By End User, 2022 & 2030 (%)

Figure 5 Global Optic Neuritis Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Optic Neuritis Treatment Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 7 Idiopathic Optic Neuritis Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 8 Multiple Sclerosis-Related Optic Neuritis Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Neuromyelitis Optica (NMO) Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 10 Toxic Optic Neuropathy Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 11 Others Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 12 Global Optic Neuritis Treatment Market Y-o-Y Growth, By Treatment, 2022-2030 (%)

Figure 13 Steroidal Therapy Treatment in Global Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 14 Immunomodulators Therapy Treatment in Global Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 15 Other Treatments Treatment in Global Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 16 Global Optic Neuritis Treatment Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 17 Hospitals End User in Global Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 18 Clinics End User in Global Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 19 Ambulatory Surgical Centers End User in Global Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 20 Others End User in Global Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 21 Global Optic Neuritis Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 22 North America Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 23 Asia-Pacific Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 24 Europe Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 25 South America Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 26 Middle East and Africa Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 27 North America Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 28 North America Optic Neuritis Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 29 North America Optic Neuritis Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 30 North America Optic Neuritis Treatment Market Share, By End User, 2022 & 2030 (%)

Figure 31 North America Optic Neuritis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 32 South America Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 33 South America Optic Neuritis Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 34 South America Optic Neuritis Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 35 South America Optic Neuritis Treatment Market Share, By End User, 2022 & 2030 (%)

Figure 36 South America Optic Neuritis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 37 Europe Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 38 Europe Optic Neuritis Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 39 Europe Optic Neuritis Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 40 Europe Optic Neuritis Treatment Market Share, By End User, 2022 & 2030 (%)

Figure 41 Europe Optic Neuritis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 42 Asia-Pacific Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 43 Asia-Pacific Optic Neuritis Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 44 Asia-Pacific Optic Neuritis Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 45 Asia-Pacific Optic Neuritis Treatment Market Share, By End User, 2022 & 2030 (%)

Figure 46 Asia-Pacific Optic Neuritis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 47 Middle East & Africa Optic Neuritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 48 Middle East & Africa Optic Neuritis Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 49 Middle East & Africa Optic Neuritis Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 50 Middle East & Africa Optic Neuritis Treatment Market Share, By End User, 2022 & 2030 (%)

Figure 51 Mallinckrodt Pharmaceuticals: Financials

Figure 52 Teijin Pharmaceutical Limited: Financials

Figure 53 AbbVie (Allergan PLC): Financials

Figure 54 AdvaCare Pharma: Financials

Figure 55 Novartis AG: Financials

Figure 56 Trethera Corporation: Financials

Figure 57 Santen Pharmaceuticals Corp: Financials

Figure 58 Teva Pharmaceutical Industries Ltd: Financials

Figure 59 Genentech, Inc: Financials

Figure 60 Alexion Pharmaceuticals, Inc: Financials

세계 시신경염 치료 시장 – 2023-2030

Global Optic Neuritis Treatment Market - 2023-2030